Search - tctmd.com

Displaying 281 - 300 of 739

Sort: Relevancy | Date

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

News Conference News

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

November 15, 2021

GIRAF: Cognitive Outcomes Similar With Dabigatran, Warfarin in Older AF Patients

News Conference News AHA 2021

GIRAF: Cognitive Outcomes Similar With Dabigatran, Warfarin in Older AF Patients

November 14, 2021

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

News Daily News

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

Michael O'Riordan

October 28, 2021

Stimulants Linked to Early Risk of CV Events in Elderly

News Daily News

Stimulants Linked to Early Risk of CV Events in Elderly

Michael O'Riordan

October 25, 2021

Starting DOACs Early After Ischemic Stroke Appears Safe

News Daily News

Starting DOACs Early After Ischemic Stroke Appears Safe

October 21, 2021

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

October 15, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

FDA Issues New Guidance on Sodium Targets for Food Industry

News Daily News

FDA Issues New Guidance on Sodium Targets for Food Industry

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT

News Daily News

Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT

Michael O'Riordan

October 04, 2021

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

News Features

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

September 28, 2021

Cumulative Burden of LDL Cholesterol Increases CHD Risk

News Daily News

Cumulative Burden of LDL Cholesterol Increases CHD Risk

Michael O'Riordan

September 23, 2021

Switching to Tenecteplase for Stroke Thrombolysis May Boost Outcomes

News Daily News

Switching to Tenecteplase for Stroke Thrombolysis May Boost Outcomes

September 09, 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

News Conference News ESC 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Michael O'Riordan

September 02, 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

STEP Trial Supports Lower BP Goal in Older Patients With Hypertension

News Conference News ESC 2021

STEP Trial Supports Lower BP Goal in Older Patients With Hypertension

August 30, 2021

News Conference News ESC 2021

SMART-MI: Implant IDs Large Burden of Arrhythmic Events Post-MI

Michael O'Riordan

August 27, 2021

Colchicine Lowers CVD Risk No Matter When Past ACS Occurred: LoDoCo2

News Daily News

Colchicine Lowers CVD Risk No Matter When Past ACS Occurred: LoDoCo2

Michael O'Riordan

August 26, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.